Form 4: Cartesian Therapeutics Director Timothy Springer Reports Multiple Common Stock Purchases

Director Timothy Springer reports several purchases of Cartesian Therapeutics (RNAC) common stock made indirectly through his wife between January and March 2024, along with holdings through TAS Partners LLC.

Summary

• Timothy Springer, a director and 10% owner of Cartesian Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• Between January 17, 2024, and March 18, 2024, Springer's wife purchased common stock in multiple transactions at varying prices.
• These purchases ranged from $0.5305 to $0.69 per share.
• The total number of shares purchased during this period was 17,600.
• Following these transactions, the number of shares beneficially owned indirectly by Springer through his wife increased to 104,818.
• Springer also directly owns 7,471,625 shares of common stock.
• Additionally, Springer indirectly owns 33,043,849 shares through TAS Partners LLC, where he is the managing member.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's stock purchases suggest confidence, but the amounts are relatively small compared to overall holdings.

Positives

• The director's purchases could be interpreted as a positive signal about the company's prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company believe its stock is undervalued.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Cartesian Therapeutics.

Key Dates